Compare · CBUS vs NITO
CBUS vs NITO
Side-by-side comparison of Cibus Inc. (CBUS) and N2OFF Inc. (NITO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBUS and NITO operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- CBUS carries a market cap of $129.8M.
- Over the past year, CBUS is up 6.6% and NITO is down 86.5% - CBUS leads by 93.1 points.
- CBUS has more recent analyst coverage (4 ratings vs 0 for NITO).
PerformanceCBUS-4.26%NITO-86.45%
2025-12-22+0.00%2026-07-24
- Company
- Cibus Inc.
- N2OFF Inc.
- Price
- $1.69-5.34%
- $1.25+32.98%
- Market cap
- $129.8M
- -
- 1M return
- +22.99%
- -15.54%
- 1Y return
- +6.65%
- -86.45%
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 0
- 0
- Recent ratings
- 4
- 0
Latest CBUS
- SEC Form S-8 filed by Cibus Inc.
- SEC Form S-8 filed by Cibus Inc.
- Europe Recognizes Nature-Based Plant Improvement, Opening a New Pathway for Cibus
- CEO Wichner Craig was granted 894,309 shares (SEC Form 4)
- Cibus Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation
- Cibus Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Finn Mark Terrence
- SEC Form 4 filed by Director Moretti August J
- SEC Form 4 filed by Director Riggs Rory B
Latest NITO
- SEC Form PRE 14A filed by N2OFF Inc.
- N2OFF Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- N2OFF Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure
- N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company
- MitoCareX Bio Reports Successful Results in Vitro: MITOLINE™-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases
- Chief Executive Officer Palach David was granted 100,000 units of Restricted Shares of Common Stock (SEC Form 4)
- Controller Zakai Shlomo was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)
- Director Weiss Amitay was granted 116,286 units of Restricted Shares of Common Stock (SEC Form 4)
- Chief Financial Officer Barda Lital was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)
- In Spaceflight Conditions: N2OFF's MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions